MBX Biosciences
Advancing potential breakthrough medicines for endocrine diseases of substantial medical need.
Launch date
Employees
Market cap
-
Enterprise valuation
€523m (Public information from Aug 2024)
Carmel Indiana (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $25.3m | Debt | |
$34.6m | Series A | ||
* | $115m | Series B | |
* | $63.5m Valuation: $575m | Series C | |
* | N/A | $188m | IPO |
| Total Funding | €194m | ||
Recent News about MBX Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.